---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Administration"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Administration. Topics: Route: intravitreal injection, Injection procedure in the phase 1 glaucoma studies, and Sham procedure in ARCHER II. 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/administration"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Route: intravitreal injection

> “It is formulated for intravitreal (IVT) administration, with the potential to be the first targeted vision-preserving therapy for GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

> “Form: solution for injection; Route of Administration: IVT injection”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-2.1.2.10.2-2"></a>

### Injection procedure in the phase 1 glaucoma studies

> “Intravitreal injection was performed under sterile conditions. Topical proparacaine was used for anesthesia. Lid margins were cleaned with Povidone-iodine 10% and povidone-iodine 5% was applied to the conjunctival surface, including the injection site.”
> “For ANX007 injection, the needle was inserted perpendicular to the sclera, 3.5 to 4 mm posterior to the limbus, between the vertical and horizontal rectus muscles.”
> “Intraocular pressure was checked postinjection. Topical antibiotics were not used postinjection.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.10.2-3"></a>

### Sham procedure in ARCHER II

> “Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-2.1.2.10.2-4"></a>

### Needle gauge, delivery device, and post-injection monitoring instructions for the commercial product

No evidence found.

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
